Data from 37 advanced NSCLC patients receiving nivolumab enrolled in clinical trials have demonstrated a strong correlation between the level of gut microbiome diversity and anti-PD-1 antibody efficacy in advanced NSCLC Chinese patients (Jin et al., 2019). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.